HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 05, May 2018 – Dental health - The root to good health       » Drugs to watch 2018       » Dragonfly-inspired nano coating kills bacteria upon contact       » New compound improves stroke recovery in monkeys and mice       » Cancer stem cell therapy breakthrough       » Draft genome of tea plant sequenced      
INSIDE INDUSTRY
Amorfix enters into agreement with a major global pharmaceutical company for Alzheimer's disease diagnostic
Amorfix Life Sciences Ltd., an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases, has signed an agreement with a major global pharmaceutical company to use the human Alzheimer's disease diagnostic assay in phase 1 clinical studies.

Amorfix has granted its collaborator access to its proprietary EP-AD assay technology and the Company will complete assay optimization and validation prior to using the assay as part of a clinical trial to investigate the effects of a novel therapeutic for the treatment of Alzheimer's disease. The terms of the agreement have not been disclosed.

"We are very excited to be working with a world-class pharmaceutical company with the resources and expertise to assist in the further development our human Alzheimer's disease diagnostic assay technology. The Company has worked very hard to create a diagnostic test that can identify patients with early-stage disease and we are gratified to have the opportunity to assist in the clinical development of new therapeutics that may offer improved treatment options for Alzheimer's disease patients" said Dr. Robert Gundel, Amorfix President and CEO. "In addition, this agreement is an example of our business plan to establish effective partnerships and strategic alliances with companies that have the resources and expertise to help advance our products to clinical development and commercialization".

The EP-AD diagnostic assay is capable of identifying early-stage Alzheimer's disease patients and patients with mild cognitive impairment (MCI) who are at high risk of developing Alzheimer's disease. The EP-AD assay measures levels of Abeta aggregates, a known biomarker of Alzheimer's disease, and can also be used to monitor the effects of Alzheimer's disease treatments on Abeta aggregates, the building blocks of plaques that form in the brains of people with Alzheimer's disease.
information, future events or otherwise.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy